Medicine Recommendations

Opioid induced bowel dysfunction in palliative care (NICE TA 277 terminated)

NICE is unable to recommend the use in the NHS because no evidence submission was received from the manufacturer of the technology

NICE TA277 - Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)

ADHD in children, adolescents and adults

NICE guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management

Acute Gout (as per LSCMMG Guidelines)

Nausea associated with Acute Migraine

MHRA Drug Safety Update - Metoclopramide: risk of neurological adverse effects

Nausea and vomiting

Opioid-induced nausea and vomiting

Treatment of patients with chronic heart failure with resistant volume overload.

Treatment of documented ventricular arrhythmias which, in the judgement of the physician, are considered as life-threatening.

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Status Epilepticus

MHRA Drug Safety Update - Buccal midazolam (Buccolam▼): new authorised medicine for paediatric use

Status Epilepticus

Breathlessness

Care in the last weeks or days of life - Breathlessness in the last days of life AND Agitation/terminal restlessness in the last days of life

Palliative care emergencies - Seizures AND Anixolytic following major blood loss

Postural hypotension

Termination of pregnancy

Susceptible infections

Symptoms of overactive bladder (NICE TA290)

NICE TA290 - Mirabegron for treating symptoms of overactive bladder

*FOR BLACKPOOL CCG ONLY* - Where antimuscarinic agents are contraindicated or not tolerant.

*FOR MORECAMBE BAY CCG ONLY* - Mirabegron is recommended second line after at least two other NICE recommended therapies have been tried and either failed or not tolerated.

*FOR GREATER PRESTON, CHORLEY & SOUTH RIBBLE CCGS ONLY* - Restricted to third line use as per TA

Depressive illness

Depressive illness, social phobia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Narcolepsy

MHRA Drug Safety Update - Modafinil: now restricted to narcolepsy

Pain

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Breathlessness

Pain in the last weeks or days of life

Breathlessness in the last days of life

Pain